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The range of possible nanostructures is so large and continuously growing, that collating and unifying the knowledge 
connected to them, including their biological activity, is a major challenge. Here we discuss a conception that is based on 
connection of microscopic features of the nanomaterials to their biological impacts. We also consider what would be 
necessary to identify the features that control their biological interactions, and make them resemble each other in a 
biological context.  
1 Introduction  
In the generations to come, mankind will be able to systematically 
make, characterise, and harness for use a great variety of nanoscale 
objects of different sizes, surfaces and shapes. The capacity to 
engineer at this scale will be of some importance for a very broad 
range of applications. Besides that, new approaches for engineering 
hard-material ranging from orthopaedic implants to car tyres, and 
new processing scenarios, such as 3D printing and nanolithography, 
will lead to new varieties of shape or process-induced particles 
differing from those found in naturally occurring dusts. The future 
therefore involves many more forms of nanoparticles, all in contact 
with the living world, than those that have been discussed in recent 
years.  
We consider that the future will be marked by an increasing 
diversity of nanoparticle structure, including different surfaces, 
shapes, and topologies. While it has been striking just how little 
conventional short-term (acute) “toxicity” is associated with the 
vast majority of particles studied to date,1 clearly caution in the face 
of radically new scenarios is still wise. Furthermore, we fully expect, 
and our own experience suggests, that these novel forms to exhibit 
interesting biological properties, and that those will in many cases 
lead to important and useful medical applications.  
To undertake investigations of such an extensive arena, future 
scientists will also consider not just the practical importance of the 
topic, but how it is positioned within the tapestry of conceptual and 
fundamental science. Succinctly put, is it important, and will it lead 
to new phenomena and ideas? We believe it will, partly based on 
our own experience, as well as the scientific context defined by the 
size. 
Thus crucially, objects on the nanoscale engage with living systems 
in an entirely different manner to either small molecules, or large 
(micron sized) particles.2-5 Engineered particles being of some tens 
of nanometers are distinctive because they can engage with 
essentially all endogenous active biological processes, potentially 
leading to diverse complex biological outcomes.  
 
Figure 1: Time lapse spinning disk confocal microscope images of 
green fluorescent polystyrene (PS-COOH) nanoparticles (100 nm) 
entering an A549 cell where the membrane is stained in red with 
CellMask™ Orange. When the particle crosses the membrane the 
colour appears as yellow (green/red overlapping).  
_______________________________________________________ 
 
In Fig. 1 we can see an example of a common polystyrene 
nanoparticle (green) passing across the cell membrane (red), using 
the energy supplied by the cell, after (biomolecules adsorbed on 
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the particle surface) have been recognised by specific cell receptors, 
rather than the non-specific diffusional processes by which the 
majority of small molecules enter cells.6-8 This example is one of 
many, and living organisms are usefully viewed as the most complex 
and effective nanoscale processing devices in existence. Whatever 
we, in our generation, are able to achieve, the capacity to engineer 
objects on the size scale of such biological phenomena clearly 
defines a unique new frontier that will grow and deepen across 
generations. 
Now, our capacity to engineer NPs with different sizes, shapes and 
surfaces ensures that within cells, barriers and organs, a new 
universe of objects, some of them with surfaces and shapes never 
previous exposed to living organisms, will be brought into contact 
with the sophisticated biological processing machinery that can 
analyse them and respond to them using an extensive repertoire of 
pre-existing biological “pathways”, essentially biological processing 
subroutines. We do not know the boundaries and capacities of that 
endogenous processing machinery, when it confronts such novel 
scenarios.  
The choices in making nanoparticles are so extensive and, unlike 
molecules, not governed by the rules and constraints of chemical 
bonding as to be almost limitless in composition and structure. This 
is rather akin to the situation with snowflakes: structures often 
grow by kinetic control, allowing for a range of shapes and 
variations that make it difficult to systematically name them, rather 
than simply showing pictures of them. 
Thus, in practical terms, many new nanoscale objects are being 
reported in the literature or experienced in the living world without 
any form of categorisation, cross referencing to previous structures, 
or systematic naming strategy. There is no means to even check if 
such a structure has been identified and studied before. Therefore 
the basic desire would be that manufacturers of new nanoparticles 
could immediately identify if similar structures (according to the 
material, size, shape, and other physical features) have previously 
been made, if for no other reason than to avoid naming similar 
materials by different names.  
If this process of systematisation could also support the progressive 
unveiling of the connection between the relevant (microscopic) 
control parameters of these nanomaterials and biological impacts, 
this would focus our energy on the drive for positive safe 
nanotechnology developments, and new health-promoting 
products. While fully recognising the magnitude of the challenge, 
these are compelling reasons now to address the whole question of 
categorisation, in a manner that intersects with the emerging 
understanding of biological interactions.  
1.1 Categorisation and Classification 
We have stressed the idea that, at the nanoscale, biological 
interactions occur by active biological processes, intended to 
process naturally occurring biomolecules. However, current 
discussions about nanomaterial classification take place in the 
context where nanomaterials are under particular scrutiny for their 
potential to improve medical therapeutics9-11 and diagnostics,12, 13 
as well as their risk of exposure to ecosystems.14, 15 Regulatory 
bodies, industry, infrastructures and institutions, aware of potential 
exposure risks, have maintained a watch on both risks and benefits 
of new nanotechnology. Therefore there is a need to understand, 
harness, and systematise the emerging scientific information that 
could impinge on these fields.  
Before beginning the discussion we should briefly consider the 
concepts of categorisation, identity, similarity, as well as the 
fundamental purpose and drivers for the effort.  We must clearly 
differentiate between a desire to (a) identify and parameterise 
nanoparticles (e.g., surface and shape) that enables them to be 
“searchable” in databases, and (b) organise and classify using key 
parameters that control, for example, important biological 
responses. The former is a typical challenge in any Internet-based 
search or match for similarity categorisation, possibly based on a 
few simple qualities. The meaning and complexity of this can be 
illustrated with the following analogy: motorcars might be 
identified as being in the same category quite readily from their 
images, but, for example, vacuum cleaners (given the novelty of 
design of several different recent versions) may not be, as they can 
look quite different. In the case of image-only-based searches for 
vacuum cleaners we would have to be satisfied to recognise those 
that are currently typical. On the other hand, if we genuinely seek 
to build in a deeper contextualisation of the data (for example, 
“items that use a vacuum to clean floors”) then an overall analysis 
of the physical form of the device may not be sufficient. For vacuum 
cleaners this is easy, because the manufacturers tell us clearly what 
the purpose is. Translating these considerations and concepts to 
nanoparticles is challenging because when a new nanoparticle type 
is made, the purpose and the context might not yet be clear.  
On the other hand if we decide to add context to the nanoparticle 
concept of categorisation, by making a long list of properties, there 
is no reason to suppose this will lead to useful insights. Our 
perspective will be that we wish to capture key (microscopic) 
information from nanoparticles that could enable a connection to 
biological impacts. By analogy with the car, we do not wish to 
catalogue ever bolt and plate used to manufacture it, nor simply to 
hope to recognize its purpose on the internet from its “form”. 
Instead we wish to capture granular information (for example, it 
has four wheels, a steering wheel, pistons and cylinder) that is 
central to how it acts in meaningful environments. In our case this 
means that we are not seeking to describe it at single atomic, 
molecular level, or by a list of “properties” but by semi-microscopic 
features that are likely to define its biological interactions. This 
allows us to “name” the object based on those features, and also to 
promote the meaningful link between its form and biological 
processes it induces, all within the same framework. For example, 
we will argue that features derived from particle shape, and 
particular biological recognition motifs presented at the surface 
have a similar status to the “wheels and pistons” of a car. 
We note that quite different (non-microscopic) proposals have 
been published in an attempt to bring a generalised nomenclature 
system to nanostructures16, 17 in addition to early classification 
systems.18-20 So far, classification of nanomaterials sometimes 
begins with their size definition, i.e. a nanomaterial is routinely 
defined as a material containing particles or constituents of 
nanoscale dimensions, in the size range from 1–100 nm.21-23 An 
early attempt to systematise nomenclature of nanomaterials was 
based on a typographic string of minimalist hierarchical codes 
aimed at facilitating digital archiving and search strings for specific 
properties that address composition, size, shape and 
physicochemical properties.16 This schematic code includes the 
following five fields: chemical class, size and shape, core chemistry, 
ligand chemistry, and solubility. Efforts to address issues of 
toxicology based on physicochemical properties introduced the 
Minimal Information About Nanomaterials (MIAN) for 
physicochemical characteristics established by the Nanomaterial 
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Registry.19, 24 In parallel, progress has been made to further 
characterise nanomaterials for general purposes by organisations 
such as the Organisation for Economic Co-operation and 
Development (OECD), the International Organization for 
Standardization (ISO), the Food and Drug Administration (FDA), and 
the National Cancer Institute (NCI).10, 17, 25 These proposals are the 
best efforts so far in the midst of highly uncertain current 
knowledge of the real material control factors for biological 
outcomes. One cannot expect a single final broad and inclusive 
approach to categorization to emerge for some time to come so 
these are all useful contributions in an era when those discussions 
are being progressed. Thus, we propose to offer a “horizon” 
perspective on a quasi-microscopic conception of the arena, and 
show how that might grow over the coming decade.  
Herein, we wish to illustrate a form of categorization based on 
molecular and microscopic principles. Such considerations will link 
more directly to the biological interactions and biological processes, 
and the connections between them. We do not seek to minimise 
the long-term challenges in such a project, but stress that it does 
have the merit of providing a durable focus and purpose in 
understanding the biological impact of these materials, which could 
have many useful outcomes, besides the process of categorization 
itself.  
It is difficult to be very definitive, but in our discussion we have in 
mind particles that do not dissolve or degrade too rapidly so that 
their size, shape and surface coating (both manufactured and 
acquired from the environment) are relatively fixed for some time. 
Roughly speaking such particles carry their shape and key elements 
of their surface presentation into the cell where many are 
ultimately deposited in degradative organelles such as lysosomes or 
phagosomes.26 The soft outer surface may then be degraded within 
five hours, but other aspects of the particle form may be degraded 
only over weeks months or years.27 Importantly, the initial 
interactions governed by molecular features at the interface 
between nanoparticles and biological systems strongly shape the 
biological properties of nanomaterials. For instance, in the first 
hours, the bio-distribution is determined, and immunological 
responses (e.g. inflammatory response) are initiated. Later on, as 
the whole particle degrades, it will be necessary to go much deeper 
into the molecular identities of the degradation products.  
1.2 Current Context of Particle Architecture 
The way in which nanomaterials are made and reported is 
qualitatively different from chemicals. For instance, in synthesis, the 
promotion of one crystal plane growth and the slowing of another 
(using surface active agents for example) typically leads to non-
spherical objects,28-35 and understanding how to control such 
parameters leads to increasingly rich structures. To clarify the 
magnitude of the problem, we remark that even fine tuning the 
plasmon resonance of metallic gold nanoparticles can lead to 
creating a number of subtle variants of the particle shape that are 
often described with a large variety of arbitrary and increasingly 
exotic names. A few examples reported in the literature (Fig. 2) are, 
nanodisco balls,36 describing the complex nanoarchitectures 
obtained by self-assembly of spherical polymeric nanoparticles and 
nanocrystals, branched nanoparticles37, 38 are often reported as 
nanourchins,39 nanoflowers,40-42 daisy shaped43 or star shaped29, 44 
and asymmetric silver nanoparticles are reported as nanocarrot 
structures45. Sometimes the shape morphology given by specific 
surface modification is described as nano-fruit texture, for example, 
nano-raspberries and nano-cranberries.46 The need to name these 
in this interim fashion is entirely unavoidable. However, these 
examples represent only a tiny part of the structures that scientists 
are currently, or soon will, fabricate using only metals.  
Using different materials, there is a huge variety of potential 
structures and compositions, and the choice is limited only by the 
imagination. Moreover, their composition may not be uniform, and 
for many purposes different core materials have to be considered. 
The variety of materials used in these structures has implications 
for the biological impact. Some may leach free ions (that are 
themselves toxic) and have multiple biological actions.47, 48 
Examples include some quantum dots, and lead-based perovskites 
(film photovoltaic devices/solar cells).49, 50 Leeching is the simplest 
form of biological processing and (for example liver) accumulation 
may lead to degradation, and formation of secondary metabolites, 
all of which would need to be accommodated in a full (biologically 
relevant) molecular description of the nanomaterial.  
These will all have to be addressed in due course, but as a first step 
we wish to illustrate how a form of biologically relevant 
categorization could emerge based on key microscopic control 
parameters that are currently emerging. These are parameters that 
link directly to molecular or microscopic structural properties, and 
are currently believed to be have a degree of universality in their 
impact on the biology, irrespective of the nature of the material. 
We are not yet sure we know all of them, but we are clear that the 
list includes size, shape, and surface presentation of the 
nanomaterial, and that these fix certain key control parameters 
affecting the biology.  
 
Figure 2: Examples of exotic shape of NPs in the literature: a) 
polymeric nanodisco balls (TEM micrograph)36, b) gold nanoflowers 
(TEM micrograph)42, c) silver nanocarrots (TEM micrograph)45, d) 
polymeric nanoraspberries (phase AFM image)46. Reprinted with 
permission from American Chemical Society. 
_______________________________________________________ 
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2 Key Microscopic Control Parameters for Complex 
Nanostructures Parametrisation 
We now have ample evidence that at least size, shape, and surface 
presentation impacts on the biological processes induced by 
nanoparticles. In understanding how to link properties to outcomes, 
one well established approach is to form a reference library of 
objects in which those key parameters are evolved, and study the 
biological outcome. This is indeed one of the approaches we have 
taken. Thus, in Fig. 3a we show a partial catalogue of complex 
nanostructures (the “nanoparticle library”) developed within our 
laboratory. While such structures can have an almost limitless 
possibility of combinations, even for the limited set between size, 
shape and surface modifications, as summarised in Fig. 3b, we are 
attempting to distil the actual collection into a smaller set that 
highlights structural changes believed to induce qualitatively new 
(from spherical) biological processes, thereby illustrating the 
concept of key control parameters.  The names of the particles 
(found in the caption) are related to their geometrical appearance 
whilst observing them by Transmission Electron Microscopy (TEM) 
and we remind the reader that all of these descriptions are 
somewhat idealised, because not all particles in a typical sample are 
identical. The majority of the general discussion is therefore 
centred on the typical, average, or “idealised” nanoparticle in the 
sample. This concept of diverse objects, and sample-containing 
“outliers” will be further discussed in the following section. 
 
Figure 3: a) Transmission Electron Microscopy (TEM) micrographs of Nanoparticles Shape Library developed within CBNI.51 From the top 
left: gold nanotrisoctahedra, faceted gold nanorods (top view), gold nanocubes, gold nanorods, gold nanoprisms, gold nanostars and 
urchin-like, few layer graphene flakes and commercial nanodiamonds. Scale bars are 100 nm. b) The scheme summarises the multitude of 
possibilities in terms of the combination of size, core material, shape and other physical properties, surface chemistry, functionalisation 
which will be further modified by biological environment.  
_________________________________________________________________________________________________________________
2.1 Nanoparticle Samples Containing Diverse Objects with 
Different Individual Properties 
Before beginning, it is important to clarify a central message: 
individual nanoparticles interact with individual cells. The concept 
of “average nanoparticle”, or indeed “average cell” may be relevant 
if all nanoparticles interact with all cells in much the same way. 
However, all batches of nanomaterials made by current means, no 
matter how high their quality, are fundamentally samples 
containing huge numbers of somewhat different nanoparticles. 
Furthermore, some samples can contain a relatively small number 
of “exceptionally” shaped, or otherwise organised nanoparticles 
(Fig. 4). For their overall functional properties (whether in devices 
or consumer products) this presents no problems of any kind. On 
the contrary, tiny levels of “outliers” in, for example, surface, 
degree of crystallinity, or shape, are quite irrelevant, in much the 
same manner that small levels of chemical contaminants are 
irrelevant for the required function. The question here is not quite 
so simple. If a relatively small number of exceptional particles exist 
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in a sample, with a highly specific shape or other notable property 
that could lead to cellular damage then, because of the potential 
for damaged cells to multiply and amplify the effects (for example 
in tumours), then they could be significant. We note that there is at 
present no substantive reported case where this could raise 
concern. However, we noted that this article constitutes an attempt 
to clarify understanding and to support the framing of a long-term 
strategy. Small numbers of non-degradable, unclear nanoparticles 
could reside for long durations in novel biological contexts, and it 
would be wise to keep that in mind, albeit without undue emphasis, 
in the framing of a general strategy. 
 
 
Figure 4: TEM micrograph of “exceptionally” shaped nanoparticles 
(red circles) in the same batch of seemingly monodisperse gold 
nanorods. 
_______________________________________________________ 
It is also worth commenting that characterisation of complex 
nanostructures has presented significant challenges, but some 
progress is now being made. Most characterisation methods in 
dispersions (e.g. dynamic light scattering - DLS, and differential 
centrifugal sedimentation - DCS and others) involve measurements 
of relaxation time, from which one spatial dimension can be 
determined but have limitations to reveal complex features. The 
development of new techniques such as Single Particle Scattering 
and extinction technique (SPES)52, 53 and Analytical 
Ultracentrifugation (AUC)54 especially with multi wavelength 
functionality (MLW-AUC)55 has broaden our capacity in analysing 
complex shapes and size range of nanomaterials in dispersion. 
Combining these advanced techniques with more routine 
instrumentation (DCS and DLS) and high resolution imaging (High 
Resolution-Transmission Electron Microscopy, Scanning TEM) we 
can obtain a higher level of characterisation and shape recognition 
that will soon be indispensable. 
Now, assuming that one has a set of particles in which key control 
parameters have been evolved, one must still be able to capture 
and quantify those control parameters on a scale that is 
meaningfully related to the biology. The degree to which current 
methods of characterization, and those being developed, can link 
directly to key control parameters will be an important 
consideration for the future strategy in development of 
nanoparticle characterization technologies, and it is by no means 
clear that methods becoming available are sufficient to do so. To 
some degree one must accept all of the developments supporting 
these efforts will be iterative. As we identify key control 
parameters, we will need to investigate the modes of 
characterization necessary to capture these quantities. In the 
interim, we believe that some broad approaches, such as ones 
involving shape digitization of images discussed below, are proving 
very fruitful in capturing the necessary information from which 
critical parameters can be identified.  
2.2 Capture of Key Control Parameters: Shape Digitisation  
Unlike for simple spherical nanomaterials, there are no obvious 
means to describe the particle form or shape. For nanoparticles 
with well-known geometrical shape (rods, cubes) the classification 
and naming can appear straightforward, but on the other hand, 
more complex anisotropic or branched nanostructures require 
special geometrical descriptors. Cubic or spherical nanoparticle can 
be easily identified and classified based on classic geometry while 
the so-called “nanostars” represent a variety of complex shapes 
with several similarities (Fig. 5). 
 
 
Figure 5: TEM micrographs of so-called, a) gold nanostars and b) 
gold short-tipped nanostars (also referred to as urchin-like 
nanoparticles). The insets underline the remarkable shape variation 
between the objects in the sample despite the classification as 
stars. Scale bars are 100 nm. 
_______________________________________________________ 
One approach is therefore to capture the structures in digital form 
so that the forms can be analysed, stored and processed, and key 
control parameters progressively identified from them. 
Mathematical quantities derived from their shape can be computed 
directly, and hypothesis of “search driven” efforts made to relate 
those to biological impacts. This is not a simple question of 
characterisation, but of sufficiently resolved information to ensure 
that key parameters are encompassed. The simplest and most 
generally applicable method of determining shape is electron 
microscopy, applied to sufficient numbers of particles to form a 
statistical basis.56  In the case of complex nanoparticles and 
nanoparticle assemblies it is possible to capture the 3D model of 
particles from TEM-based tomography using image reconstruction 
processes.57 Systematic construction of an extensive collection of 
wire-frame models of complex nanoparticles can then be used to 
yield a database of descriptors for each particle kind using 
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algorithms to process the individual samples in a high throughput 
fashion.58-60  
 
2.3 The importance of the nanoparticle surface to biological 
impacts 
The nature of the “bare” nanoparticle surface can be extraordinarily 
complex, and certainly it is this “bare” surface that will be 
important in understanding long term effects when coatings have 
been degraded off the surface within biological subsystems such as 
phagosomes and lysosomes. However, we are now essentially 
certain that the early stages of biological response for materials 
depends on what is presented on the surface2, 61, 62 in situ rather 
than only the original bare surface. Molecules, especially 
biomolecules derived from the biological milieu, such as blood and 
lungs lining, are adsorbed onto the surface (see scheme in Fig. 6a). 
If this does not occur, then, of course, efforts to study particle 
interactions with cells will lead to spurious and damaging 
interactions due to the high energy surface disrupting the cell.2, 63 
Thus, for cell level studies, the simplest role of the corona coating is 
to ensure sensible exposure conditions for cells. Recent innovations 
now allow the recognition motifs presented at the surface of 
nanoparticles to be fully mapped out using immuno-reporter and 
other simple and inexpensive devices.64 This means that a rather 
complete description of the in situ surface may be given.  
It is essential to stress that simply nanoparticle adsorbed molecules 
may not themselves induce a specific biological response, but for 
molecules with specific biological functions such as receptor 
recognition motifs, such functions can be preserved and amplified 
when presented on the nanoparticle surface. Also, other value 
chain modifications of the nanoparticle could be of importance 
either by being the source of some new biological outcomes or by 
modifying the adsorbed coronas. Thus, if biologically active 
molecules from the environment adsorb onto the surface, this 
could be important. A simple example is the case of 
lipopolysaccharide (LPS) derived from bacterial debris and widely 
present in the environment. This is a biologically active molecule 
that, when presented on the nanoparticle surface could lead to a 
high level of biological activity.65 Succinctly put, when nano-objects 
are presented to living organisms, the sum of all (particularly bio-
active) molecules presented on the outer surface, whether from the 
value chain or from body entry by different routes, is a key factor to 
understanding early biological impacts.61, 66-72  
Most experience so far suggests that the majority of biologically 
active molecules (apart from LPS and other microbial components) 
on the surface of nanoparticles in vivo are derived after exposure to 
the endogenous biomolecules of the organism itself, rather than 
derived from the broader environment. In any case, the methods to 
screen for surface presentation of molecules are becoming so 
inexpensive and simple that it is practical to screen for a huge 
variety of outcomes, and identify if there are any other (biologically 
important) surface anomalies that are derived from the broader 
environment.  
In summary then, we are now essentially certain that (besides size) 
the shape and in situ presentation of biomolecules at the surface of 
nanoparticles are key control parameters for biological impacts. 
Furthermore, the methods to study these are now available, or 
emerging, and it is thus feasible to show how a categorization 
approach could be built on this kind of input. We stress that this 
does not exclude many other known (for example degradation or 
dissolution) effects or as yet unknown parameters. It merely begins 
the process of organizing the data around what we are most 
confident in. 
3 Biological Pathways as the fundamental 
Biological Targets  
The enormous variety of possibilities for nanoparticles properties, 
and the difficulty in condensing those into clearly defined key 
control parameters is matched by the complexity of biological 
processes that could be affected by nanoparticles.  
One broad approach, based on our own experience and 
accumulated knowledge from different disciplines, suggests that 
part of the effort could be focused to collect and systematically 
rationalise the activation of the currently known biological 
pathways by nanomaterials, and connect them to specific features 
of the nanoparticles.7, 73-79 Such pathway maps already comprise of 
a high level of widely available accumulated knowledge on the 
potential biological targets of the system. Briefly, these pathways 
constitute a basic grouping of the ‘subroutines’ of a cell (or cell 
assembly) that are required to make the cell function, elements of  
which can be up-regulated, or down-regulated in the context of an 
external perturbation.  
While far from a complete description of all biological events, they 
constitute a well-organised body of information that has developed 
over time about the connected biological processes that make cells 
function. Thus, knowledge of the impact of nanomaterials on these 
pathways will suggest many of the largest and most significant 
biological outcomes.  
If one finds that different particles activate predominantly similar 
biological actions, or groups of pathways, then it will be natural to 
ask if those similarities in activation of pathways are based on a 
common material property, possibly as yet unidentified. If so, this 
will progressively unveil the detailed features of nanomaterials that 
represent “commonalities” between particles. This idea is closely 
related to the capacity to “read-across” mentioned earlier, between 
the known impacts of one set of materials to the likely outcomes of 
another, and how to apply this knowledge in a systematic way. Such 
an approach to systematizing the biological impact is far from 
complete, but fits rather well in seeking to understand the 
microscopic connection between biological processes and key 
control parameters.  
3.1 Hypothesis driven exploration of nanoparticle-biological 
impacts 
For some nanoparticle key parameters (shape and surface 
presentation) we can readily hypothesize the involvement of 
specific pathways, and even potentially suggest higher level in vivo 
impacts. One example is the connection of surface presentation of 
recognition motifs of nanoparticles in situ to specific biological 
pathways. To illustrate this, we focus on biological pathways of 
practical importance and show how surface presentation can be 
used to organise information about them. There is nothing special 
about our choice of example, and the same process can be carried 
out for many others. 
Thus, we will consider the issue of liver accumulation, which is 
important in understanding the toxicity of nanomaterials, both for 
general safety, and for medical applications.80-82 The role of the liver 
is to monitor the bloodstream for presence of undesirable foreign 
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materials, which it may then remove and degrade. Evidently, if it 
removes more foreign material than it is designed to accommodate, 
or if that foreign material degrades to produce new toxins, this 
could lead to liver damage. For medical applications, it is usually 
desirable to evade the liver, as one is targeting other locations.  
Thus determining and categorising the likely outcome of 
nanomaterials on the liver is an important task undertaken in any 
safety assessment, for all products, whether consumer or 
medicinal. Extensive knowledge of the liver architecture (Fig. 6a) 
suggests that the nature of the cells, and thereby the outer 
membrane receptors, leads to the accumulation of biomolecules 
and various debris that should be cleared. In practice, for example, 
there are less than twenty key receptors believed to dominate the 
process of receptor mediated liver accumulation. Thus, by matching 
the molecules presented at the surface of nanoparticles in situ (Fig. 
6b) with the receptors (and associated pathways) on the surface of 
cells of the liver, we can suggest how those particles could interact 
with the liver, and via which mechanisms and processes. To 
illustrate, in a recent study we have shown that many forms of 
amorphous silica in human serum and plasma present recognition 
motifs for both low-density lipoprotein (LDL) and immunoglobulin G 
(IgG), suggesting that they will be recognized by liver mechanisms 
using a designed to handle cholesterol and infections.64 
Moreover, the molecular structures and the relative abundance of 
these surface biomolecules have been obtained through mass 
spectrometry and various proteomics, lipidomics, glycomics, 
amongst other approaches,83-90 the results of a more complete 
mapping exercise are now becoming available.91, 92 These mapping 
methods now give information at the molecular level, establishing if 
all of the potential recognition motifs are actually expressed on the 
nanoparticle surface in an accessible manner to receptors. This now 
leaves us with a clear set of hypotheses that links the nature of the 
molecules on the surface to the impact on cells. It is significant that, 
by working at this level of description it now becomes meaningful 
to ask how “similar” (at these early timescales) nanoparticles are on 
the basis of their surface presentation of recognition motifs 
(“epitope maps”). This therefore provides an avenue to categorise 
them, at least in relation to such things as bio-distributions, early 
immunological processing, etc.  
Figure 6: a) Schematic representation of the liver architecture and zoom of the interaction between nanoparticle-corona complex and cell 
receptors in the liver sinusoid; Kupffer cells express a multitude of receptors able to selectively recognise specific epitopes on the 
nanoparticle surface. b) Schematic representation of the in situ immuno quantum dots epitopes mapping approach92. The identified 
epitopes presentation can be then linked to specific receptor-mediated uptake pathways (adapted from Monopoli et al.)93.  
_________________________________________________________________________________________________________________
4.2 Databasing Based on Microscopic Principles of Interaction 
The use of microscopic, mesoscopic structural information and 
molecular (recognition) principles as the basis for linking properties 
to biological outcomes makes possible new ways of collecting and 
organizing the information. Furthermore, the methods are available 
(for example epitope mapping and shape digitization) to approach 
the set of tasks in a logical and systematic manner. While the 
approach does require significant effort, some of the methods are 
also relatively inexpensive, and in vivo is a final specific step, rather 
than the basis of the great body of knowledge. The workflow 
depicted in Fig. 7, can then be used to capture systematic 
knowledge, gathered in different laboratories, potentially ultimately 
providing the basis to predict the nature of the early stages of 
biological interaction on living organisms.  
This then constitutes a clear strategy and successful approach to 
both categorise and to read-across, for early stage impacts based 
on the nature of the surface of nanomaterials. Obviously such a full 
categorisation will also have to include any other major overarching 
effects, one of which we believe to be shape, as well as any specific 
properties of interest for a specific material.  
 
Page 7 of 11 Nanoscale Horizons
N
an
os
ca
le
H
or
iz
on
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
13
 M
ar
ch
 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
3/
03
/2
01
7 
17
:0
6:
30
. 
View Article Online
DOI: 10.1039/C6NH00219F
  
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 8  
Please do not adjust margins 
Please do not adjust margins 
 
Figure 7: Schematic representation of the hypothesised workflow for nanomaterials bioclassification based on their intrinsic 
physicochemical properties (e.g. shape) and epitope presentation of biomolecular corona. This classification is closely linked to the in vitro 
and in vivo profiling of nanomaterials. Typically, in vitro profiling includes identification of receptors for corona recognition, intracellular 
trafficking, and subsequent signal pathway activation due to exposure to nanomaterials. Such in vitro data will be correlated with in vivo 
behaviour of the nanomaterials in a given animal model, whereby immunological response and biodistribution are determined. The 
proposed bioclassification will facilitate the correlation between in vitro and in vivo, providing the potential of prescreening nanomaterials 
to be tested in vivo. 
_________________________________________________________________________________________________________________ 
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Conclusions 
There is little doubt that a review such as this, written a decade 
from now, when so many of the issues that are currently uncertain 
will have been resolved will be much more complete. However, 
such an idealized academic perspective does not make useful 
connection to the real world in which we live. Key questions are 
being posed now, and decisions being made based on current 
discussions. Rather, our aim here has been instead to make 
concrete “horizon” proposals that can be acted on now, with the 
hope of being more mature within a decade.  
We stress it is too early to decide whether the approach expounded 
here, in which microscopic information is linked to biological 
outcomes, will become most central. For example, at the time of 
writing, more “informatics” related approaches that a posteriori 
harvest information that is accumulated without any driving force 
from microscopic science are favoured by some scientists. And 
there are many other alternatives also. The relative merits and 
difficulties of all of these options will only clarify in time, and it is 
premature to impose a single direction on our thinking.  
However, if one wishes to retain the option of linking microscopic 
and structural nanomaterial principles to biology, then information 
collected over the coming decade must respect some guiding vision, 
of categorization or systematization, or it will be difficult to 
integrate later into any meaningful overall picture. Currently we 
have high levels of confidence that size, shape and surface 
presentation in situ will determine much of the early stages of 
biological impacts. At later stages of biological interaction we 
believe (but still there is much to be done to prove) that the 
degradation products produced in intracellular degradative 
organelles will be important.  
It need hardly be stressed, after a decade of such discussions, that 
one should characterise nanomaterials (for example particle surface 
properties) by every approach available, and record as many 
properties as possible. Still, for truly microscopic understanding it 
will be necessary to identify the key (microscopic) control 
parameters, and this may require detail that does not flow directly 
from current characterization methods. While we believe we are 
beginning to understand these issues, it makes sense now to 
capture all of the information that could encompass the control 
parameters that could be used to check those hypotheses, and may 
ultimately be useful in framing a systematization of the field.  
Thus, it makes sense now to have initiatives to fully capture (for 
example digitize) the shapes (and their distributions) of particles, 
for this will would allow the progressive uncovering of those 
(control) structural features that lead to different outcomes, at a 
time when we do not know all the features that lead to significant 
new outcomes. Similarly, the knowledge of the biological 
recognition fragments (via epitope mapping and other methods) 
presented at the surface will also allow for a direct link to 
immediate biological outcomes, including immune response, 
biodistribution, and others.  
Also, increased focus on the manner in which the materials are 
processed and degraded, (leading to specific molecular details of 
metabolites) within cells will also be valuable as one seeks to 
understand longer time scales of biological impacts.  
The progressive digitization of such information now would allow us 
to build a searchable and addressable database that will identify if 
similar forms (based on computable automated metrics) had 
previously been synthesised, and thereby attach attendant 
information, and new information derived for example from the 
study of other pathways as that becomes available. This database 
would thus index those material forms also with what we believe to 
be the key metrics of biological responses, and provide a list of 
expected biological pathway response that could arise, allowing the 
user to confirm these, or critically annotate that database.  
While for some (non-degrading) materials we expect the material, 
size, shape, and (intra-organelle) surface to continue to dominate 
the subsequent story, the tools that we have to link all of these 
ideas together are currently more limited. For materials that evolve 
significantly within organisms (dissolve, degrade etc.) we can at 
least be sure that the (molecular) classification of degradative 
pathways will be important. No doubt, for chronic long-term 
exposure there is lack of tools for credible mechanistic studies. Still 
we are confident that the basic framework outlined here will evolve 
smoothly into new forms that will allow us to deal with longer-term 
issues, and have begun work on that topic.  
We argued at the beginning that the nanoscale in contact with 
living processes is distinctive, because biology was (uniquely) built 
to process on the nanoscale. Thus, we consider that, whatever the 
trends and fashions of science, knowledge and understanding of the 
engineered nanoscale in contact with biology is of durable value, 
and this is particularly true of understanding based on microscopic 
principles.  Thus, unlike many incremental scientific enterprises, the 
systematization and microscopic understanding of engineered 
nanoscale objects interacting living organisms, while it has been 
commenced by this generation of scientists, belongs to all 
generations, and will attract the durable attention and interest of 
scientists across generations. Investment, if wisely crafted, will not 
be wasted in such a scientific arena.  
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